PARP1 and ovarian serous adenocarcinoma: A study on the loss of BRCA1 and p53 and overexpression of c-Myc in high-grade serous ovarian cancer model of syngeneic genetically engineered mouse showed that PARP inhibitors induced the activation of the STING pathway, accompanied by an increased expression of IFNβ, PD-L1, and CXCL10 (71).